China Tobacco and Alcohol Group Limited (ZY)
| Market Cap | 1.02B |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 204.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ZY
China Tobacco and Alcohol Group is a next-generation tobacco and alcohol conglomerate leveraging artificial intelligence (AI) and blockchain technology to revolutionize the global tobacco and alcohol industries. We operate across three key business segments. 1. We utilize AI-driven analytics, machine learning, and biotechnology to develop innovative, high-quality tobacco and alcohol products tailored to evolving consumer preferences and regulatory standards. 2. We own and operate state-of-the-art manufacturing facilities, producing premium toba... [Read more]
News
SEC Charges Zymergen Inc. With Misleading IPO Investors About Company's Market Potential and Sales Prospects
Washington, D.C.--(Newsfile Corp. - September 13, 2024) - The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology co...
Ginkgo Bioworks Completes Acquisition of Zymergen
BOSTON and EMERYVILLE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo ...
ZYMERGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zymergen - ZY
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zymergen Inc. (N...
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ
NEW YORK , Aug. 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates IEA, ZY, FLAC
NEW YORK , July 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million
The deal values Zymergen at a fraction of its $3 billion valuation at Zymergen's IPO last April.
Ginkgo to Acquire Zymergen
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science...
Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform
Octant doubles its initial investment in Zymergen's Automation Technology to significantly increase the scale and throughput of its drug discovery platform Octant doubles its initial investment in Zym...
Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications
EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use...
Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform
EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation syst...
Zymergen Reports Preliminary First Quarter 2022 Financial Results
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the first quarter ended March 3...
Zymergen to Participate in the BofA Securities 2022 Healthcare Conference
EMERYVILLE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Co...
Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022
EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it will report preliminary financial results for the first quarter 2022 after market ...
Zymergen Reports Preliminary Fourth Quarter and Full Year 2021 Financial Results
EMERYVILLE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the fourth quarter and full y...
Zymergen to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on March 22nd, 2022
EMERYVILLE, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it will report preliminary financial results for the fourth quarter and full year 202...
Zymergen Advances Molecules for Prominent Malaria and COVID-19 Drug Targets for Further Testing
EMERYVILLE, Calif., March 06, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen (ZY) is pleased to announce early results from its work on infectious disease, discovering hundreds of potential n...
Zymergen to Present at the 42nd Annual Cowen Healthcare Conference
EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced the company will be participating in the upcoming 42nd Annual Cowen Virtual Healthcar...
Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morgan Healthcare Conference
Delivering platform expertise and developing novel microbes, molecules and materials for customers across a variety of markets Delivering platform expertise and developing novel microbes, molecules an...
Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World's Largest Metagenomics Databases and Proprietary Synthetic Biology Platform
Exploring natural products for innovative therapeutics Exploring natural products for innovative therapeutics
Zymergen to Present at the 40th Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen”or the “Company”), today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Virtual Heal...
The Law Offices of Frank R. Cruz Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $ZY #investors--The Law Offices of Frank R. Cruz Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors
Zymergen Reports Preliminary Third Quarter 2021 Financial Results and Provides Business Update
EMERYVILLE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), a leading biofacturing company, today reported preliminary financial results for the third quarter en...
Zymergen to Report Third Quarter 2021 Financial Results on November 3, 2021
EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (Nasdaq: ZY) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3...
The Inside Story Of How SoftBank-Backed Zymergen Imploded Four Months After Its $3 Billion IPO
Zymergen raised $500 million when it went public in April, on top of more than $1 billion in venture funding. By August, its CEO was out and the synthetic biology company wouldn't say when it might ha...